JP2025509567A5 - - Google Patents
Info
- Publication number
- JP2025509567A5 JP2025509567A5 JP2024554783A JP2024554783A JP2025509567A5 JP 2025509567 A5 JP2025509567 A5 JP 2025509567A5 JP 2024554783 A JP2024554783 A JP 2024554783A JP 2024554783 A JP2024554783 A JP 2024554783A JP 2025509567 A5 JP2025509567 A5 JP 2025509567A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320961P | 2022-03-17 | 2022-03-17 | |
| US63/320,961 | 2022-03-17 | ||
| US202263350503P | 2022-06-09 | 2022-06-09 | |
| US63/350,503 | 2022-06-09 | ||
| PCT/US2023/015347 WO2023177772A1 (en) | 2022-03-17 | 2023-03-16 | Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509567A JP2025509567A (ja) | 2025-04-11 |
| JP2025509567A5 true JP2025509567A5 (https=) | 2026-03-24 |
Family
ID=86054295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554783A Pending JP2025509567A (ja) | 2022-03-17 | 2023-03-16 | 再発性類上皮肉腫を、二重特異性抗ＭＵＣ１６ｘ 抗ＣＤ３抗体単独で、または抗ＰＤ－１抗体と組み合わせて治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4493280A1 (https=) |
| JP (1) | JP2025509567A (https=) |
| KR (1) | KR20240159849A (https=) |
| CN (1) | CN119677534A (https=) |
| AU (1) | AU2023236126A1 (https=) |
| CA (1) | CA3245946A1 (https=) |
| IL (1) | IL315405A (https=) |
| MX (1) | MX2024011298A (https=) |
| WO (1) | WO2023177772A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026015612A1 (en) * | 2024-07-10 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | Methods of treating smarcb1-deficient cancers |
| CN119632993B (zh) * | 2024-12-04 | 2025-09-23 | 安徽医科大学 | 他泽司他在制备治疗急性肾损伤的药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| EP3986934A1 (en) * | 2019-06-21 | 2022-04-27 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation |
-
2023
- 2023-03-16 IL IL315405A patent/IL315405A/en unknown
- 2023-03-16 AU AU2023236126A patent/AU2023236126A1/en active Pending
- 2023-03-16 WO PCT/US2023/015347 patent/WO2023177772A1/en not_active Ceased
- 2023-03-16 KR KR1020247033968A patent/KR20240159849A/ko active Pending
- 2023-03-16 CN CN202380034697.1A patent/CN119677534A/zh active Pending
- 2023-03-16 CA CA3245946A patent/CA3245946A1/en active Pending
- 2023-03-16 JP JP2024554783A patent/JP2025509567A/ja active Pending
- 2023-03-16 EP EP23718415.5A patent/EP4493280A1/en active Pending
-
2024
- 2024-09-13 MX MX2024011298A patent/MX2024011298A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI890661B (zh) | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 | |
| JP7126941B2 (ja) | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| AU784971B2 (en) | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies | |
| JP2022050618A5 (https=) | ||
| JP2021528423A5 (https=) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| JP2019515008A5 (https=) | ||
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2023505218A5 (https=) | ||
| JP2020508317A5 (https=) | ||
| JP2021514945A5 (https=) | ||
| JP2011507932A5 (https=) | ||
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2022512851A5 (https=) | ||
| JP2025509567A5 (https=) | ||
| WO2023217268A1 (zh) | 抗tim-3抗体与抗pd-1抗体的药物组合 | |
| JP2025134086A (ja) | 関節リウマチを有する対象における疼痛を治療するための組成物および方法 | |
| JP2023519807A5 (https=) | ||
| JP2025502061A5 (https=) | ||
| JP2022513029A5 (https=) | ||
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| CN118697865A (zh) | 治疗淋巴瘤的药物组合 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| RU2024129390A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕЙ ЭПИТЕЛИОИДНОЙ САРКОМЫ С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХАНТИТЕЛ ПРОТИВ MUC16 x CD3 САМИХ ПО СЕБЕ ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ ПРОТИВ PD-1 | |
| JP2025508832A5 (https=) |